# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare products, and Eyenovia...
HC Wainwright & Co. analyst Matthew Caufield reiterates Eyenovia (NASDAQ:EYEN) with a Buy and maintains $12 price target.